What is the ticker symbol for Zymeworks?

Zymeworks trades under the ticker ZYME on NASDAQ.

What sector does Zymeworks operate in?

Zymeworks is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ZYME in a portfolio?

PortView shows ZYME's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Zymeworks (ZYME) Stock Analysis

NASDAQHealthcareBiotechnology

$30.23+1.89%

1-year price historyRange $14.08 – $30.32

52-week range$30.23

$13.60$30.91

What Zymeworks does

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Key metrics

Market cap

$2.22B

P/E (TTM)

-14.97

EPS (TTM)

$-2.02

Beta

1.15

Dividend yield

0.00%

Revenue / share

$0.51

50-day avg

$25.14

200-day avg

$24.83

52-week high

$30.91

52-week low

$13.60

CEO

Kenneth H. Galbraith

ETFs linked to ZYME

Broad-market and Healthcare sector ETFs an investor holding Zymeworks is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how ZYME fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ZYME in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Zymeworks?: Zymeworks trades under the ticker ZYME on NASDAQ.
Which exchange is ZYME listed on?: ZYME is listed on NASDAQ.
What sector does Zymeworks operate in?: Zymeworks is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze ZYME in a portfolio?: PortView shows ZYME's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.